Cho Y, Yoon D, Khosrow-Khavar F, Song M, Kang EH, Kim JH, Shin JY. Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study. J Intern Med. 2025;297(4):366–81.

PubMed  CAS  Google Scholar 

Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Therapy. 2015;17:212.

Google Scholar 

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.

PubMed  Google Scholar 

Chatzidionysiou K, di Giuseppe D, Soderling J, Catrina A, Askling J. Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking. RMD Open 2022, 8(2).

Polesie S, Gillstedt M, Schmidt SAJ, Egeberg A, Pottegard A, Kristensen K. Use of methotrexate and risk of skin cancer: a nationwide case-control study. Br J Cancer. 2023;128(7):1311–9.

PubMed  PubMed Central  CAS  Google Scholar 

Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014;43(4):489–97.

PubMed  CAS  Google Scholar 

Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake T, Cope AP, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36–48.

PubMed  CAS  Google Scholar 

Sebbag E, Lauper K, Molina-Collada J, Aletaha D, Askling J, Gente K, Bertheussen H, Bitoun S, Bolek EC, Burmester GR et al.: 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis 2024.

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol (Hoboken NJ). 2021;73(7):1108–23.

Google Scholar 

Tanaka K, Ichikawa A, Umezawa N, Yamamoto K, Yoshifuji K, Okada K, Nogami A, Umezawa Y, Nagao T, Sakashita C, et al. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023;114(9):3719–27.

PubMed  PubMed Central  CAS  Google Scholar 

Raheel S, Crowson CS, Wright K, Matteson EL. Risk of Malignant Neoplasm in Patients with Incident Rheumatoid Arthritis 1980–2007 in relation to a Comparator Cohort: A Population-Based Study. Int J Rheumatol 2016, 2016:4609486.

Yan MK, Wang C, Wolfe R, Mar VJ, Wluka AE. Association between Low-Dose methotrexate exposure and melanoma: A systematic review and Meta-analysis. JAMA Dermatol. 2022;158(10):1157–66.

PubMed  PubMed Central  Google Scholar 

Fardet L, Nazareth I, Petersen I. Effects of chronic exposure of hydroxychloroquine/chloroquine on the risk of cancer, metastasis, and death: a population-based cohort study on patients with connective tissue diseases. Clin Epidemiol. 2017;9:545–54.

PubMed  PubMed Central  CAS  Google Scholar 

Ertz-Archambault N, Kosiorek H, Taylor GE, Kelemen K, Dueck A, Castro J, Marino R, Gauthier S, Finn L, Sproat LZ, et al. Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia. JAMA Oncol. 2017;3(7):936–43.

PubMed  PubMed Central  Google Scholar 

Strangfeld A, Hyrich K, Askling J, Arkema E, Davies R, Listing J, Neovius M, Simard J, Symmons D, Watson K, et al. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology (Oxford). 2011;50(1):146–51.

PubMed  Google Scholar 

Ren A, Fu G, Qiu Y, Cui H. Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma. Mol Med Rep. 2017;16(6):9125–30.

PubMed  CAS  Google Scholar 

Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, et al. Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: A cohort study. Arthritis Rheumatol. 2016;68(10):2403–11.

PubMed  PubMed Central  CAS  Google Scholar 

de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24–37.

Wetzman A, Lukas C, Gaujoux-Viala C, Mamtani R, Barnetche T, Combe B,. Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2023;75(2):260–71

Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: A systematic review and Meta-Analysis of observational studies. J Clin Gastroenterol. 2019;53(1):e1–11.

PubMed  PubMed Central  Google Scholar 

Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk of cancer recurrence in patients with Immune-Mediated diseases with use of immunosuppressive therapies: an updated systematic review and Meta-Analysis. Clin Gastroenterol Hepatol. 2024;22(3):499–e5126.

PubMed  CAS  Google Scholar 

Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J et al. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol. 2016;152(2):164–72.

Ruiz JI, Lei X, Chi-Fang W, Giordano SH, Zhao H, Rajan SS, Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors. Breast Cancer. 2024;31(6):1059–70.

Silva-Fernández L, Lunt M, Kearsley-Fleet L, Watson KD, Dixon WG, Symmons DPM, et al. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British society for rheumatology biologics Register-Rheumatoid arthritis. Rheumatology (Oxford). 2016;55(11):2033–9.

PubMed  Google Scholar 

Suarez-Almazor ME, Ruiz JI, Lei X, Wu CF, Zhao H, Rajan SS, et al. Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer. Clin Rheumatol. 2024;43(11):3301–12.

PubMed  PubMed Central  Google Scholar 

Phillips C, Zeringue AL, McDonald JR, Eisen SA, Ranganathan P. Tumor necrosis factor Inhibition and head and neck cancer recurrence and death in rheumatoid arthritis. PLoS ONE. 2015;10(11):e0143286.

PubMed  PubMed Central  Google Scholar 

D’Arcy ME, Beachler DC, Pfeiffer RM, Curtis JR, Mariette X, Seror R, et al. Tumor necrosis factor inhibitors and the risk of cancer among older Americans with rheumatoid arthritis. Cancer Epidemiol Biomarkers Prev. 2021;30(11):2059–67.

PubMed  PubMed Central  Google Scholar 

Ruiz JI, Lei X, Wu CF, Zhao H, Giordano SH, Rajan SS, et al. Utilization of biologic Disease-Modifying antirheumatic therapy in patients with rheumatoid arthritis and recently diagnosed breast cancer. Arthritis Care Res (Hoboken). 2024;76(6):850–9.

PubMed  Google Scholar 

Chatzidionysiou K, Delcoigne B, Frisell T, Hetland ML, Glintborg B, Dreyer L, et al. How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open. 2020;6(2):e001363.

PubMed  PubMed Central  Google Scholar 

Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, et al. Malignancy risk with Tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL surveillance trial. Ann Rheum Dis. 2023;82(3):331–43.

PubMed  Google Scholar